FLT3 and acute myeloid leukemia: Bone marrow is the preferred specimen for FLT3 mutation assessment in both newly diagnosed and R/R AML;Testing on peripheral blood is acceptable if bone marrow is not available, provided that sufficient blasts are present;Caution is advised regarding the interpretation of results from low-blast count blood or marrow specimens;